In a report released on May 10, Richard Newitter from Truist Financial maintained a Hold rating on Globus Medical (GMED – Research Report), with a price target of $63.00. The company’s shares closed last Friday at $64.72.
Newitter covers the Healthcare sector, focusing on stocks such as Intuitive Surgical, Teleflex, and Nevro Corp. According to TipRanks, Newitter has an average return of 15.9% and a 58.50% success rate on recommended stocks.
In addition to Truist Financial, Globus Medical also received a Hold from JMP Securities’s David Turkaly in a report issued on May 9. However, on the same day, Barclays maintained a Buy rating on Globus Medical (NYSE: GMED).
GMED market cap is currently $8.74B and has a P/E ratio of 102.53.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Globus Medical (GMED) Company Description:
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.
